BACKGROUND: Cardiopulmonary disease is associated with an increased risk of severe respiratory syncytial virus (RSV) disease in adults. This study estimated the potential public health impact of adjuvanted RSVPreF3 vaccination in adults 50-59 years of age (YOA) with select cardiopulmonary diseases in the United States (US).
METHODS: A Markov model with a 3-year time horizon projected outcomes associated with one-time adjuvanted RSVPreF3 vaccination in US adults 50-59 YOA with chronic obstructive pulmonary disease (COPD) (n=3,299,241), heart failure (HF) (n=712,959), coronary artery disease (CAD) (n=2,865,359), and asthma (n=3,439,066). Model inputs were informed by scientific literature and public data sources. Outcomes, including RSV acute respiratory illness (ARI) cases, healthcare resource use, and mortality, were compared between scenarios with and without vaccination, assuming the same vaccination coverage as for influenza vaccines in this age group (50.1%).
RESULTS: Without vaccination, 3-year cumulative RSV-ARI cases in adults 50-59 YOA were projected to range from 117,232 to 573,262 in the HF and asthma populations, respectively. One-time adjuvanted RSVPreF3 vaccination resulted in 22,730 to 110,668 fewer RSV-ARI cases for HF and asthma, respectively. An estimated 582, 237, 392, and 294 RSV-related deaths were avoided by vaccination in the COPD, HF, CAD, and asthma populations, respectively. Vaccination prevented the loss of 3,081 to 8,860 quality-adjusted life years across populations when accounting for reduced RSV-related morbidity and mortality.
CONCLUSIONS: Findings suggest that the adjuvanted RSVPreF3 vaccine has the potential to substantially reduce RSV burden among US adults 50-59 YOA with cardiopulmonary diseases.
